Bait and Switch: the Great Ketamine “Breakthrough” | RxISK
Here's Why Sage Therapeutics Rose as Much as 20.3% Today | The Motley Fool
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
sage-10k_20161231.htm
Sage surges after depression drug gets rapid path to approval - PMLiVE
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration | Sage Therapeutics, Inc.
Biogen signs $1.5bn depression drug deal with Sage Therapeutics
Sage Therapeutics Forges $575 Million Deal With Shionogi to Market Depression Drug in Parts of Asia | BioSpace
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Reports Positive Top-Line Results from Phase II Placebo-Controlled Trial of SAGE-217 in MDD - Drug Discovery and Development
Sage Therapeutics Announces Promising Zuranolone Phase 3 Findings for Major Depression
Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression | BioSpace
Breakthrough Agitation Agent; Demi Lovato's Bipolar Misdiagnosis? | MedPage Today
Sage Therapeutics' SAGE-217 Receives FDA's Breakthrough Designation for CNS Disorders
sage-10k_20181231.htm
SAGE Therapeutics shares rocket after FDA clearance to expedite its depression post-partum drug SAGE-217
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
Keeping up with the clinical advances: depression | CNS Spectrums | Cambridge Core
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Sage Therapeutics surges 70% after depression drug breakthrough
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
